Industry Workshops provide an opportunity for AMCP corporate members to highlight their latest drug therapies, technologies, and a wealth of products and services affecting professionals working in managed care pharmacy.
All Industry Workshops take place on Wednesday, March 30, from 11:30am–12:30pm.
Materials presented in workshops may be promotional and concentrate on a specific product, service, or therapeutic area. Therefore, these presentations are considered promotional and do not offer continuing education credit.
Endeavor Rx: An FDA-Cleared Interactive, Nonpharmacological Digital Therapeutic for Pediatric ADHD
Description: In this workshop, EndeavorRx, a digital therapeutic indicated to improve attention function in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue will be reviewed. The session will begin with an overview of Akili Interactive and focus on Prescription Digital Therapeutics engineered to treat cognitive impairments, that represents an entirely new category of medicine. This will be followed by a review of the key clinical attributes of EndeavorRx, relevant to the management of pediatric ADHD. Finally, the results of pivotal studies, including study design, key clinical endpoints, and safety profile of EndeavorRx will be presented.
- Eddie Martucci, PhD, Co-Founder and Chief Executive Officer
- Gregory Lyles, Vice President, Market Access
Sponsored by Akili Interactive
The Current State of Major Depressive Disorder: Understanding the Implications of the Burden of Illness and Unmet Need
Description: The burden of major depressive disorder (MDD) is greater than ever in the United States – exacerbated by the COVID-19 pandemic. While the use of antidepressants has increased over the last decade, so has the prevalence of MDD. This expert-led presentation will explore the clinical, humanistic, and economic challenges experienced in the United States resulting from MDD’s growing burden of illness and the unmet need in treating adult patients with MDD. Following the presentation will be an expert panel discussion on the burden of MDD, with perspectives represented from key opinion leaders in neuroscience, healthcare payers and patient advocacy.
- Gary Owens, MD, President, Gary Owens Associated Medical Management, Pharmaceutical Consulting
Andrew Cutler, MD, Chief Medical Officer, Neuroscience Education Institute
Phyllis Foxworth, VP, Peer and Policy Advancement Depression and Bipolar Support Alliance
Zachary Contreras, PharmD, Director, Pharmacy Benefits, Sharp Health Plan
Sponsored by Sage Therapeutics and Biogen Inc.
Ibrexafungerp: The First Oral Glucan Synthase Inhibitor for Treatment of Fungal Infections
Description: This presentation will introduce a first-in-class, non-azole, oral treatment option for women with vulvovaginal candidiasis (VVC), including a review of clinical trial data for this novel agent.
Join us as we discuss the impact of VVC on women and the evolving challenge of providing effective treatment.
The second half of the program will discuss the SCYNEXIS pipeline, new data, and clinical development program.
- David Kriesel, PharmD, Senior Director, Medical Affairs, SCYNEXIS, Inc.
- Michael Krychman, MD, Executive Director, Southern CA Center for Sexual Health & Survivorship Medicine; Clinical Faculty Member, University of Southern California; Clinical Health Professor, Department of OBGYN / Division of Gynecology Oncology, University of California, Irvine
Sponsored by Scynexis Inc
Industry Workshops with a PIE logo include preapproval information exchange information. Subject to federal laws and regulations, attendance at these sessions is restricted to payors, formulary committee, or other similar entity representatives with knowledge and expertise in health care economic analysis, carrying out responsibilities for the selection of drugs for coverage or reimbursement. Look for additional details on the PIE information page.
There may be Industry Workshop sponsorship opportunities available for AMCP Corporate Members in good standing for Nexus 2022. Contact Laura Larson, assistant director, national meeting sales, at email@example.com for more details.